Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
about
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesRole of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.Casein kinase 1α: biological mechanisms and theranostic potential.
P2860
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inactivation of CK1α in multip ...... n survival signaling pathways.
@en
Inactivation of CK1α in multip ...... n survival signaling pathways.
@nl
type
label
Inactivation of CK1α in multip ...... n survival signaling pathways.
@en
Inactivation of CK1α in multip ...... n survival signaling pathways.
@nl
prefLabel
Inactivation of CK1α in multip ...... n survival signaling pathways.
@en
Inactivation of CK1α in multip ...... n survival signaling pathways.
@nl
P2093
P2860
P50
P356
P1433
P1476
Inactivation of CK1α in multip ...... n survival signaling pathways.
@en
P2093
Anna Cabrelle
Gianpietro Semenzato
Gregorio Barilà
Ketty Gianesin
Laura Bonaldi
Laura Quotti Tubi
Matteo Costacurta
Paolo Macaccaro
Renato Zambello
Sara Canovas Nunes
P2860
P304
14604-14619
P356
10.18632/ONCOTARGET.14654
P407
P50
P577
2017-01-14T00:00:00Z